Search results for "Pyrimidine"

showing 10 items of 589 documents

CCDC 180277: Experimental Crystal Structure Determination

2002

Related Article: E.Breuning, G.S.Hanan, F.J.Romero-Salguero, A.M.Garcia, P.N.W.Baxter, J.-M.Lehn, E.Wegelius, K.Rissanen, H.Nierengarten, A.van Dorsselaer|2002|Chem.-Eur.J.|8|3458|doi:10.1002/1521-3765(20020802)8:15<3458::AID-CHEM3458>3.0.CO;2-Y

bis(mu~3~-26-bis(4-(5-(2-pyridyl)-2-pyridyl)-2-phenylpyrimidine-6-yl)pyridine)-tris(mu~2~-26-bis(4-(5-(2-pyridyl)-2-pyridyl)-2-phenylpyrimidine-6-yl)pyridine)-hexa-cobalt(ii) dodecakis(tetrafluoroborate) unknown solvateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients.

2007

Increasing evidence suggests that the quality-rather than just the quantity-of low-density lipoproteins (LDLs) exerts a great influence on cardiovascular risk. LDLs comprise multiple subclasses with discrete size and density, and different physicochemical composition, metabolic behaviors, and atherogenicity. Individuals generally cluster into 2 broad subgroups. Most have a predominance of large LDLs, and some have a higher proportion of small particles. Small, dense LDLs are good predictors of cardiovascular events and progression of coronary artery disease. Their predominance has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Tre…

cardiovascular riskRiskStatinmedicine.drug_classHypercholesterolemiasubclassePharmacologyBioinformaticschemistry.chemical_compoundClofibric AcidEzetimibemedicineHumansPharmacology (medical)Cholesterol absorption inhibitorRosuvastatinRisk factorRosuvastatin CalciumNational Cholesterol Education ProgramSulfonamidessmall dense LDLfibrateCholesterolbusiness.industryAnticholesteremic AgentsstatinGeneral MedicineCholesterol LDLEzetimibeFluorobenzenesRosuvastatin CalciumPyrimidineschemistrydiabeteCardiovascular DiseasesAzetidineslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessrosuvastatinmedicine.drugAdvances in therapy
researchProduct

CCDC 903522: Experimental Crystal Structure Determination

2013

Related Article: Diana Visinescu, Luminita Marilena Toma, Oscar Fabelo, Catalina Ruiz-Pérez, Francesc Lloret, and Miguel Julve|2013|Inorg.Chem.|52|1525|doi:10.1021/ic302278q

catena-((mu2-22'-Bipyrimidine)-hexakis(mu2-cyano)-bis(110-phenanthroline)-tetranitrato-dicyano-diaqua-di-praseodymium-di-iron)Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 188051: Experimental Crystal Structure Determination

2003

Related Article: J.M.Herrera, D.Armentano, G.de Munno, F.Lloret, M.Julve, M.Verdaguer|2003|New J.Chem.|27|128|doi:10.1039/b206124b

catena-((mu~2~-22'-Bipyrimidine)-hexakis(mu~2~-cyano)-diaqua-dicyano-di-manganese(ii)-molybdenum(iv))Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1848844: Experimental Crystal Structure Determination

2018

Related Article: Donatella Armentano, Adrián Sanchis-Perucho, Carlos Rojas-Dotti, José Martínez-Lillo|2018|CrystEngComm|20|4575|doi:10.1039/C8CE00996A

catena-(bis(mu-bromo)-(mu-22'-bipyrimidine)-tetrachloro-copper-rhenium chloroform solvate)Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 843439: Experimental Crystal Structure Determination

2012

Related Article: N.Marino, D.Armentano, G.De Munno, J.Cano, F.Lloret, M.Julve|2012|Inorg.Chem.|51|4323|doi:10.1021/ic202740b

catena-(bis(mu~2~-fluoro)-(mu~2~-22'-bipyrimidine)-di-fluoro-diaqua-di-copper(ii))Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 843438: Experimental Crystal Structure Determination

2012

Related Article: N.Marino, D.Armentano, G.De Munno, J.Cano, F.Lloret, M.Julve|2012|Inorg.Chem.|51|4323|doi:10.1021/ic202740b

catena-(bis(mu~2~-hydroxo)-(mu~2~-22'-bipyrimidine)-di-copper(ii) hexa-aqua-manganese(ii) hexafluorosilicate tetrahydrate)Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1953086: Experimental Crystal Structure Determination

2020

Related Article: Gemma F. Turner, Fallyn Campbell, Stephen A. Moggach, Simon Parsons, Andrés E. Goeta, M. Carmen Muñoz, José A. Real|2020|Angew.Chem.,Int.Ed.|59|3106|doi:10.1002/anie.201914360

catena-(octakis(mu-cyano)-diaqua-bis(pyrimidine)-di-iron-tetra-silver dihydrate)Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1953087: Experimental Crystal Structure Determination

2020

Related Article: Gemma F. Turner, Fallyn Campbell, Stephen A. Moggach, Simon Parsons, Andrés E. Goeta, M. Carmen Muñoz, José A. Real|2020|Angew.Chem.,Int.Ed.|59|3106|doi:10.1002/anie.201914360

catena-(octakis(mu-cyano)-diaqua-bis(pyrimidine)-di-iron-tetra-silver dihydrate)Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 249690: Experimental Crystal Structure Determination

2005

Related Article: V.Niel, A.L.Thompson, A.E.Goeta, C.Enachescu, A.Hauser, A.Galet, M.C.Munoz, J.A.Real|2005|Chem.-Eur.J.|11|2047|doi:10.1002/chem.200400930

catena-(tetracontakis(mu~2~-Cyano)-octakis(mu~2~-pyrimidine-NN')-octa-iron(ii)-tetracosa-silver)Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct